跳至主要内容
临床试验/NCT04000204
NCT04000204已完成不适用

The Comparison of Safety and Effectiveness Between HYAJOINT Plus and Bioventus Durolane for the Treatment of Knee Osteoarthritis Pain

SciVision Biotech Inc.2 个研究点 分布在 1 个国家目标入组 142 人开始时间: 2017年6月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
142
试验地点
2
主要终点
The change from baseline VAS pain score at 6 months post-injection.

研究概览

简要总结

The aim of this study is to compare the safety and effectiveness between two BDDE-crosslinked hyaluronate, HYAJOINT Plus and Durolane, for the Treatment of Knee Osteoarthritis Pain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
35 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age from 35 to 85 years;
  • radiographic Kellgren-Lawrence grade II to III;
  • symptoms ≧6 months despite conservative treatments such as analgesics, NSAID and/or physical therapy;
  • average knee pain score ≧30mm on 100-mm visual analog scale (VAS) in recent one week;
  • radiographic evidence of bilateral knee OA not reason for exclusion if VAS pain in contralateral knee <30mm.

排除标准

  • previous orthopedic surgery in the lower extremity;
  • disabling osteoarthritis of hip or ankle;
  • previous IAHA within 6 months;
  • IA steroid or joint puncture within 3 months;
  • characters of severe acute synovitis under ultrasound (US) examination, such as Grade 3 in suprapatellar synovitis (SPS), suprapatellar effusion (SPE), medial compartment synovitis (MCS) or lateral compartment synovitis (LCS);
  • Any specific medical condition, such as rheumatoid arthritis, Lupus erythematous, hemiparesis, infection, neoplasm, and etc., that would interfere with assessments;
  • confirmed or suspected pregnancy or lactating;
  • known allergy history to any avian protein or HA product.

结局指标

主要结局

The change from baseline VAS pain score at 6 months post-injection.

时间窗: 6 months post-injection

The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'

次要结局

  • Adverse events reported from the baseline and during the study period(1, 3, 6, 9 and 12 months post-injection)
  • Knee joint inflammatory state change by ultrasonic inspection(Baseline, 1, 3, 6, 9 and 12 months post-injection)
  • Visual analog scale (VAS) score for pain change(Baseline, 1, 3, 9 and 12 months post-injection)
  • Visual analog scale (VAS) score for satisfaction change(1, 3, 6, 9 and 12 months post-injection)
  • Timed Up-and-Go test (TUG) change(Baseline, 1, 3, 6, 9 and 12 months post-injection)
  • Single-leg stance test (SLS) change(Baseline, 1, 3, 6, 9 and 12 months post-injection)
  • The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Likert scale score change(Baseline, 1, 3, 6, 9 and 12 months post-injection)
  • Visual analog scale (VAS) score for stiffness change(Baseline, 1, 3, 6, 9 and 12 months post-injection)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验